Applied DNA announces publication of peer-reviewed journal article on linearDNA

Applied DNA Sciences announced the publication of a peer-reviewed research article in "Molecular Therapy – Methods & Clinical Development," whose initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022. "The study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines. Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses," the company stated. "This peer-reviewed publication supports the innovative work we and our partners are conducting to advance linearDNA as a potential new class of human and veterinary therapeutics that combines the rapid design and manufacturing capabilities akin to mRNA therapies with the thermostability and relative manufacturing simplicity of linearDNA. Adding to already robust data supporting the potential of linearDNA in-hand, this study and others being conducted and planned make a compelling case for linearDNA as a next-generation, DNA-based vaccine platform, in addition to its utility in the manufacture of other nucleic acid-based therapies, such as mRNA and CAR T therapies," added Dr. James A. Hayward, president and CEO of Applied DNA.